Comparison results
| Results: Differences General | ✘Neurofibromatosis | ✘Systemic aspergillosis | ||||||||||
| Related research | Analogs | Analogs | ||||||||||
| ||||||||||||
| Distinctive symptoms | ||||||||||||
| Register, to see more distinctive signs of diseases and studies | 100% | — | ||||||||||
| Register, to see more distinctive signs of diseases and studies | — | 100% | ||||||||||
| heel spur | 96% | — | ||||||||||
| systemic aspergillosis | — | 98% | ||||||||||
| bone growths on the legs | 93% | — | ||||||||||
| lung aspergilloma | — | 61% | ||||||||||
| nose bruises easily appear | 81% | — | ||||||||||
| chronic leukemia | — | 47% | ||||||||||
| convulsions | 79% | — | ||||||||||
| acute leukemia | — | 44% | ||||||||||
| bone growths | 75% | — | ||||||||||
| immunodeficiency | — | 44% | ||||||||||
| varicose veins of the legs | 71% | — | ||||||||||
| chronic granulomatous disease | — | 38% | ||||||||||
| bruise | 70% | — | ||||||||||
| skin cancer | — | 37% | ||||||||||
| skin compaction | 70% | — | ||||||||||
| metastases | — | 33% | ||||||||||
| venous mesh on legs | 70% | — | ||||||||||
| bacteremia | — | 32% | ||||||||||
| recklinghausen 's neurofibromatosis | 68% | — | ||||||||||
| sepsis | — | 32% | ||||||||||
| veins swelling on the legs | 68% | — | ||||||||||
| a history of organ transplantation | — | 32% | ||||||||||
| cramps in the legs | 67% | — | ||||||||||
| abscess | — | 32% | ||||||||||
| veins bloating | 63% | — | ||||||||||
| impaired lung function | — | 28% | ||||||||||
| neurinoma | 63% | — | ||||||||||
| history of surgery | 15% | 35% | ||||||||||
| neurofibroma | 57% | — | ||||||||||
| leukemia | 23% | 38% | ||||||||||
| impaired venous function | 54% | — | ||||||||||
| papules | 19% | 31% | ||||||||||
| cns tumors | 47% | — | ||||||||||
| blood diseases | 16% | 27% | ||||||||||
| wilms ' tumor | 46% | — | ||||||||||
| cancer | 25% | 29% | ||||||||||
| meningioma | 44% | — | ||||||||||
| skin problems | 23% | 27% | ||||||||||
| brain cancer | 44% | — | ||||||||||
| dystrophy | 43% | — | ||||||||||
| milk rashes | 41% | — | ||||||||||
| ependymoma of the brain | 39% | — | ||||||||||
| glioma | 38% | — | ||||||||||
| brain tumors | 37% | — | ||||||||||
| oncology | 36% | — | ||||||||||
| optic nerve glioma | 35% | — | ||||||||||
| skin spots | 35% | — | ||||||||||
| benign neoplasms | 34% | — | ||||||||||
| neuroblastoma | 33% | — | ||||||||||
| kidney sarcoma | 32% | — | ||||||||||
| astrocytoma | 31% | — | ||||||||||
| kidney cancer | 29% | — | ||||||||||
| thin-boned | 27% | — | ||||||||||
| problems with the father | 27% | — | ||||||||||
| rashes symmetrical | 26% | — | ||||||||||
| skin dystrophy | 26% | — | ||||||||||
| false joint | 24% | — | ||||||||||
| heavy weight | 23% | — | ||||||||||
| history medical mother's | 23% | — | ||||||||||
| no joints | 23% | — | ||||||||||
| cataract | 22% | — | ||||||||||
| diseases of infants | 22% | — | ||||||||||
| brown pigmentation after rashes | 22% | — | ||||||||||
| brown spots on the skin | 22% | — | ||||||||||
| s eyes cloudy | 21% | — | ||||||||||
| epilepsy attacks | 21% | — | ||||||||||
| lymphosarcoma | 21% | — | ||||||||||
| consequences of pregnancy | 20% | — | ||||||||||
| epilepsy | 20% | — | ||||||||||
| traumatic illness | 20% | — | ||||||||||
| impaired kidney function | 18% | — | ||||||||||
| damage to the nervous system | 17% | — | ||||||||||
| childhood diseases | 17% | — | ||||||||||
| increased | 15% | — | ||||||||||
| spinal meningioma | 15% | — | ||||||||||
Instructions
Video 
- Introduce new diseases through 🔍 Search and input on the top panel using
- The table shows the most important distinguishing symptoms, tests and diagnoses related to the selected diseases.
- The higher the percentage, the more important this symptom is for the disease and vice versa. At 0%, we can say that this symptom never occurs in the disease.
- The list changes dynamically depending on the data of the current visit in the selection of therapy .
- Click on the percentageto see the suggestions from the original source.
- By using the service, you agree to user agreement.
